Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 16, 2007

View Archived Issues

CP-4126 well tolerated in solid tumor patients

Orphan Europe seeks EMEA approval of Vedrop for vitamin E deficiencies

Desvenlafaxine improves hot flushes, mood in postmenopausal women

Alcon submits amendment to NDA for Patanase

Lupin acquires majority stake in Kyowa

Wyeth and Zealand begin phase I trials on ZP-1609

FDA grants orphan drug status to recombinant fibrinogen

Enrollment complete for phase III clinical trial of pravastatin combination therapy

FDA denies approval of CX-717 clinical trials for ADHD

Affymax begins patient dosing in phase III trial of Hematide

Partial response rate reported in Davant phase II trial for colorectal cancer

Momenta evaluates M-118 in broad ACS clinical program

NS-1738, an allosteric modulator of alpha7 nAChRs improves short- and long-term memory in vivo

Phase III study of Gattex demonstrates clinical benefits

Series B financing by Metastatix to support cancer drug clinical trials

SpirH begins phase II study and opens enrollment for worldwide clinic participation

NPS sells mGluR collaboration assets to AstraZeneca

Novel NO donor shows potential in inflammatory skin conditions

Doribax approved by FDA for the treatment of cIAI and cUTI

Gilead submits marketing applications for Viread in U.S. and E.U.

NDA for Ampligen submitted by Hemispherx Biopharma

FDA approves use of Lexiva with reduced dose of ritonavir

Clinical data on PEP-005 topical gel for skin cancers presented

Recent Janssen and Astellas patents report novel therapeutic agents for thrombotic disorders

New agents for treating neurological disorders disclosed in recent patent literature

Recent patents describe new treatment options for cardiovascular disorders

The ACAT inhibitor KY-382 shows antiatherosclerotic effects in rabbits

Tamoxifen for the treatment of acute mania / News in Context

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Hippocratic loath? ‘Harm’ threat from ACIP’s proposed HBV shift
BioWorld
Individual liberty and choice vs. wider public health became one predictable hinge upon which swung the often-acerbic debates at the CDC’s Advisory Committee for...
Høeg appointment as acting CDER director tied to vaccine strategy?
BioWorld
After a more than 13-year period of stability with Janet Woodcock as the head of CDER, with Patrizia Cavazzoni taking charge during the next four years of former...
First phase of synthetic human genome project successfully completes
BioWorld
The first phase of the U.K. synthetic human genome project has successfully completed, realizing key steps in chromosome synthesis. The work has demonstrated a...